For Treatment of Spasticity in Patients with Multiple Sclerosis
Sun Pharma Advanced Research Company announced the top-line results of the Phase III efficacy study and duration of action study for Baclofen GRS.The Phase III efficacy study (CLR_09_21) was a placebo controlled randomized discontinuation study that investigated the efficacy and safety of Baclofen GRS in patients with spasticity due to multiple sclerosis.
Baclofen GRS is a novel, once-a-day formulation developed by SPARC's proprietary Gastro-Retentive System (GRS) Technology. The GRS technology uses a combination of size expansion, adhesion and flotation techniques to permit once-a-day administration.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
